
Acknowledgement of your Submission to RSC Advances - RA-ART-03-2021-002233

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Sun, Mar 21, 2021 at 12:25 AM

Reply-To: advances@rsc.org

To: nanik-s-a@fst.unair.ac.id

Cc: muhhammad.ikhlas.abdjan-2018@fst.unair.ac.id, nanik-s-a@fst.unair.ac.id, imamsiswanto@fst.unair.ac.id, alfinda-nk@fst.unair.ac.id, ytakaya@meijo-u.ac.jp, iqbal.choudhary@iccs.edu

20-Mar-2021

Dear Dr Aminah:

TITLE: Exploration of stilbenoid trimers as a potential inhibitor of Sirtuin1 enzyme using molecular docking and molecular dynamics simulation approach

Thank you for your submission to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-03-2021-002233

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

RSC Advances is a gold open access journal. If accepted, your manuscript will be published open access and the article will be subject to the appropriate article processing charge (APC). Discounted APCs and full APC waivers for corresponding authors in certain countries are available. All authors are given the option to apply for a waiver after signing the open access licence - please see the following URL for more details: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances>

Please indicate the above manuscript ID when you contact us about this submission.

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Abdjan, Muhammad - No ORCID iD Available, Aminah, Nanik - <https://orcid.org/0000-0002-2767-6006>, siswanto, Imam - No ORCID iD Available, Kristanti, Alfinda Novi - No ORCID iD Available, Takaya, Yoshiaki - No ORCID iD Available, Choudhary, Muhammad - <https://orcid.org/0000-0001-5356-3585>

If this is not how you want your name to appear on an Accepted Manuscript, please amend your ScholarOne account.

The Royal Society of Chemistry is a member of CrossCheck. Your submission may be compared against the CrossCheck database using the iThenticate plagiarism detection software. For further information, please see here: <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#crosscheck>

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,
RSC Advances Editorial Office
advances@rsc.org

If you need to contact the journal, please use the email address advances@rsc.org

Decision on submission to RSC Advances - RA-ART-03-2021-002233

2 messages

RSC Advances <onbehalf@manuscriptcentral.com>
Reply-To: advances@rsc.org
To: nanik-s-a@fst.unair.ac.id

Mon, Apr 26, 2021 at 2:15 PM

26-Apr-2021

Dear Dr Aminah:

Manuscript ID: RA-ART-03-2021-002233

TITLE: Exploration of stilbenoid trimers as a potential inhibitor of Sirtuin1 enzyme using molecular docking and molecular dynamics simulation approach

Thank you for your submission to RSC Advances, published by the Royal Society of Chemistry. I sent your manuscript to reviewers and I have now received their reports which are copied below.

I have carefully evaluated your manuscript and the reviewers' reports, and the reports indicate that major revisions are necessary.

Please submit a revised manuscript which addresses all of the reviewers' comments. Further peer review of your revised manuscript may be needed. When you submit your revised manuscript please include a point by point response to the reviewers' comments and highlight the changes you have made. Full details of the files you need to submit are listed at the end of this email.

Please submit your revised manuscript as soon as possible using this link:

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/rscadv?URL_MASK=0c4b6e1df5794be79ac0eb47554dc1dd

(This link goes straight to your account, without the need to log on to the system. For your account security you should not share this link with others.)

Alternatively, you can log in to your account (<https://mc.manuscriptcentral.com/rscadv>) where you will need your case-sensitive user ID and password details.

You should submit your revised manuscript as soon as possible; please note you will receive a series of automatic reminders. If your revisions will take a significant length of time, please contact me.

Supporting our community through Covid-19

While our publishing services are running as usual, we also know that this is a very challenging time for everyone, for many different reasons. If any aspect of the publishing process is worrying you – for example you think you may struggle to meet a pre-determined deadline – please let us know, and we will work out an answer together.

RSC Advances is a gold open access journal. If accepted, your manuscript will be published open access and the appropriate article processing charge (APC) will apply. Discounted APCs and full APC waivers for corresponding authors in certain countries are available. All authors are given the option to apply for a waiver after signing the open access licence - please see the following URL for more details: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances>

RSC Advances strongly encourages authors of research articles to include an 'Author contributions' section in their manuscript, for publication in the final article. This should appear immediately above the 'Conflict of interest' and 'Acknowledgement' sections. I strongly recommend you use CRediT (the Contributor Roles Taxonomy from CASRAI, <https://casrai.org/credit/>) for standardised contribution descriptions. All authors should have agreed to their individual contributions ahead of submission and these should accurately reflect contributions to the work. Please refer to our general author guidelines <http://www.rsc.org/journals-books-databases/journal-authors-reviewers/author-responsibilities/> for more information.

The Royal Society of Chemistry requires the submitting author to provide their ORCID iD when they submit a revised manuscript. This is quick and easy to do as part of the revised manuscript submission process. We will publish this

information with the article, and you may choose to have your ORCID record updated automatically with details of the publication.

Please also encourage your co-authors to sign up for their own ORCID account and associate it with their account on our manuscript submission system. Please note that we are unable to do this on behalf of your co-authors. For further information see: <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#attribution-id>.

I look forward to receiving your revised manuscript.

Yours sincerely,
Prof Manojit Pal
Associate Editor, RSC Advances

REVIEWER REPORT(S):

Referee: 1

Recommendation: Major revisions

Comments:

Comments to authors

The work is interesting to the audience of this journal and can be considered for publication after addressing the following concerns.

First, please correct your English throughout the manuscript. I found a lot of typos

methodology
molecular docking

In the methodology, it is not much clear whether you used PDB ID 4ZZI or 1NS, you mentioned that you obtained but in the docking you mentioned that you used 1NS., please clarify

You mentioned that the compounds were previously isolated, however, it is not clear whether the TS1 was isolated in this study or previous study. If isolated in this study, please provide the details on the isolation and characterization techniques used including nmr etc, and if not, please, provide a suitable reference.

In the methodology, you wrote "... Besides, to fix the missing residue in the receptor (loop) using Modeller 9.21 package, which is integrated with Chimera version 1.13..." this sentence to me is incomplete and hanging. Please check the English and correct.

In the methodology, docking you wrote "... The comparison of EVDW and Eele between the native ligand of the crystal structure (reference) and the native ligand docking (pose). ..." this is also hanging

molecular dynamics

The methodology here is not clear at all and have a lot of typos. This section has a lot of language problems, the english used brings a lot of confusing to the reader, I have found a lot of problem in the methodology and cannot be understood properly.

For example, Not clear whether the production was done at an NVT or NPT ensemble, it is important that author be explicit for reproducibility of their work. The minimization process is not much explicitly, did the authors minimize the each system individually and then combined the minimized system..? why..? why did not work on the complex ..?

I suggest that the whole work be read by an english expert, in its current form can not be accepted until the english has been edited.

qm/mm-gbsa

what is the changes in binding energy for the other ns e.g from 50-100, 100-150, 150-200 ns? something can happen in between. It is also important to understand what is happening...?

Results

It could be important to see how the binding of the ligand changes the secondary structure of the protein, e.g how the apo and holo protein structure changes, also by comparing to the least inhibitor and strong binding molecule.

In figure 4, TS3 shows fluctuations at 180-190 or near 200 ns, similar to 1NS shows fluctuations near 90-100 ns, what is happening at this point..? authors need to tell the physical features taking place at this region.

Is the ligand moving out the pocket..? what is the binding energy at this regions..? how is the protein changing its structure..? what is happening to the ligands..changing its conformation...?

what is reason for having large std dev in the total energy of the system..? eg -146,966 +/-803.55 , what is the units of this energy..? kcal/mol..? or kJ/mol..?, please, specify..?

How is this protein flexible in the absence of the ligand..?

Figure 6. To have a good picture on the effects of the ligand, it is good to compare the holo and the apo protein, I suggest that the authors compared this stability relatively to the free protein as well. this will establish the effects of the ligand upon binding to a protein. You have to do it for the rmsd as well and the rmsf too and other reaction coordinates you think are useful e.g distances.

It will be useful if you can show the binding energy decomposition and residue contribution obtained from qm/mm-GBSA and compared with those obtained from the docking /MD simulation.

To support fig 7 and 8, authors should compute the free energy as the function of the distance between the ligand and the protein using selected reaction coordinates e.g h-bond distances use the relationship

$F = -kBT \ln(p)$, where P is the probability..

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: No

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

Referee: 2

Recommendation: Major revisions

Comments:

I have gone through your manuscript and I have few comments to make:

In as much as docking is first step for HTVS studies, validation of the docking protocol is necessary. In this work, redocking approach has been performed. However, many atimes the selection of top hits maybe biased and as such, additional techniques can be implemented. This includes performing a Receiver Operating Characteristic (ROC) which determines the sensitivity of the protocol in picking up potential positive hits from non-potential ones. I recommend that this is performed.

Additionally, is it possible to validate these results using wet-laboratory assays?

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: No

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

Referee: 3

Recommendation: Major revisions

Comments:

The manuscript entitled "Exploration of stilbenoid trimers as a potential inhibitor of Sirtuin1 enzyme using molecular docking and molecular dynamics simulation approach" seemed to be interesting and may be considered further for RSC Advances after some revision

1. The English language and grammar needs substantial improvements throughout the manuscript.
2. Page 1, the sentence "Stilbenoid trimer is a class of polyphenol compounds that have been known to have the potential to inhibit the SIRT1 enzyme 11,12" needs further elaboration as I could not find anything significant related to this topic in ref 11 and 12. In fact I doubt if ref 11 has any relevance to this statement. Please check.
3. Next authors have commented "Structurally, the stilbenoid trimers consist of three resveratrol monomers,.....". In my opinion resveratrol are known to be activators of Sirt1 whereas authors studied the Sirt1 inhibitory potential of stilbenoid trimers. Please clarify.
4. The coverage of background literature is poor. The recent literature on identification of Sirt 1 inhibitors must be included in the introduction section.
5. Authors have mentioned that Stilbenoid trimers can be isolated from the *Dryobalanops oblongifolia* plant but it is not clear if TS1, TS2 and TS3 have been isolated and characterized earlier. This needs proper elaboration.
6. Fig 1: the trans isomer should be TS3?
7. Fig 2D: the chemical structure shown is awkward, please address the problem. Same issue with Fig S 2. Also TS2 and TS3 are same (trans isomer) in this figure.
8. One or two well-known inhibitor(s) of Sirt1 should have been used as reference compound(s) in the molecular modelling studies.
9. Besides docking studies in silico it is desirable to assess and analyse the ADMET properties of the current compounds in silico.
10. The graphical abstract or TOC is missing.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: No

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: No

Are the number of tables and figures in the manuscript appropriate and clear?: No

FILES TO PROVIDE WITH YOUR REVISED MANUSCRIPT:

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission. Please carefully check the spelling and format of all author names, affiliations and funding information. If your paper is accepted for publication, it is important this information is accurate to ensure your article is correctly indexed, which may affect citations and future funding evaluation. Please note that if you have selected Accepted Manuscript publication, the author list will appear as provided in the ScholarOne submission details until your Advance Article is published and this information is updated from your article.

- A point-by-point response to the comments made by the reviewer(s)
- Your revised manuscript with any changes clearly marked (.doc(x) or.pdf file)
- Your revised manuscript as a .doc(x) file including figures, without highlighting, track changes, etc. (If providing in TeX format instead, please also provide a final PDF version including figures). Please note that we cannot proceed with publication using a .pdf file only.

High quality images

EITHER

embedded in a doc(x) file

OR

as separate numbered Figures, Schemes or Charts in .tif, .eps or .pdf format, with a resolution of 600 dpi or greater.

AND

- A table of contents entry: graphic maximum size 8 cm x 4 cm and 1-2 sentence(s) of editable text, with a maximum of 250 characters, highlighting the key findings of the work. It is recommended authors make use of the full space available for the graphic. See our Author Guidelines for more details: ##TAG_RSC_AUTHOR_GUIDELINES##
- Your revised Electronic Supplementary Information (if any)
- Your revised CheckCIF reports (if any). Please ensure that any revised cif files have been deposited with the Cambridge Crystallographic Data Centre (CCDC) via <https://deposit.ccdc.cam.ac.uk/> before you submit your revised manuscript.

For Feature Articles/Review-type articles only:

- A photograph and biography of yourself and your co-authors. Separate photographs of each author may be supplied or if you prefer, a group photograph, saved as a .tif, .pdf or .jpeg file. The resolution of the photographs should be 600 dpi or higher. The dimensions of the photograph in the printed journal will be 4 cm wide x 5 cm high (individual photograph) or 8.3 cm wide x 5 cm high (group photograph). Individual photographs should be accompanied by a maximum of 100 words; a group photograph by a maximum of 200 words. There can be a maximum of 6 individual biographies per article.
- Copies of permissions required from other publishers to reproduce figures. Please ensure that necessary permissions are acknowledged in the figure captions in accordance with the publishers' instruction. Information on how to obtain permissions and rights that we require are given on our website at <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/licences-copyright-permissions/>
- The RSC encourages the submission of supporting information for compounds and spectra in electronic format, and these will be used to enhance the published article. For compounds, please supply mol files (exported from your chemical drawing package) as unique compounds, without R-groups or variable attachments. Spectral data such as NMR, IR, Raman, ESR should be supplied in the standard JCAMP format (.jdx files).
- You can highlight to readers references that you think are particularly important by marking them as a "Key Reference", e.g.:
1. Key reference: E Boudaher and CL Shaffer, Med. Chem. Commun., 2019,10, 682-692

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.



[Home](#)

[Author](#)

[Review](#)

Submission Confirmation

[Print](#)

Thank you for your revision

Submitted to

RSC Advances

Manuscript ID

RA-ART-03-2021-002233.R1

Title

Exploration of stilbenoid trimers as a potential inhibitor of Sirtuin1 enzyme using molecular docking and molecular dynamics simulation approach

Authors

Abdjan, Muhammad
Aminah, Nanik
siswanto, Imam
Kristanti, Alfinda Novi
Takaya, Yoshiaki
Choudhary, Muhammad

Date Submitted

11-May-2021

[Author Dashboard](#)



Submission Confirmation

 Print

Thank you for your revision

Submitted to

RSC Advances

Manuscript ID

RA-ART-03-2021-002233.R2

Title

Exploration of stilbenoid trimers as a potential inhibitor of Sirtuin1 enzyme using molecular docking and molecular dynamics simulation approach

Authors

Abdjan, Muhammad
Aminah, Nanik
siswanto, Imam
Kristanti, Alfinda Novi
Takaya, Yoshiaki
Choudhary, Muhammad

Date Submitted

20-May-2021

Acknowledgement of your revised manuscript submission to RSC Advances - RA-ART-03-2021-002233.R2

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Fri, May 21, 2021 at 3:15 AM

Reply-To: advances@rsc.org

To: nanik-s-a@fst.unair.ac.id

Cc: muhammad.ikhlas.abdjan-2018@fst.unair.ac.id, nanik-s-a@fst.unair.ac.id, imamsiswanto@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, ytakaya@meijo-u.ac.jp, iqbal.choudhary@iccs.edu

20-May-2021

Dear Dr Aminah:

TITLE: Exploration of stilbenoid trimers as a potential inhibitor of Sirtuin1 enzyme using molecular docking and molecular dynamics simulation approach

AUTHORS: Abdjan, Muhammad; Aminah, Nanik; siswanto, Imam; Kristanti, Alfinda Novi; Takaya, Yoshiaki; Choudhary, Muhammad

Thank you for your revised submission to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-03-2021-002233.R2

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

Please indicate the above manuscript ID when you contact us about this submission.

If there have been any changes to the list of authors during this revision, please inform the Editorial Office of the reason for the change. All authors must confirm they are happy with the authorship change by emailing advances@rsc.org.

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Abdjan, Muhammad - No ORCID iD Available, Aminah, Nanik - <https://orcid.org/0000-0002-2767-6006>, siswanto, Imam - No ORCID iD Available, Kristanti, Alfinda Novi - No ORCID iD Available, Takaya, Yoshiaki - No ORCID iD Available, Choudhary, Muhammad - <https://orcid.org/0000-0001-5356-3585>

If this is not how you want your name to appear on an Accepted Manuscript, please amend your ScholarOne account.

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,
RSC Advances Editorial Office
advances@rsc.org

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

Join the RSC Advances reviewer community

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Fri, May 21, 2021 at 7:09 PM

Reply-To: advances@rsc.org

To: nanik-s-a@fst.unair.ac.id

21-May-2021

Dear Dr Aminah:

Thank you for choosing to publish in RSC Advances, published by the Royal Society of Chemistry. Your paper was accepted for publication thanks to the reviewer(s) who provided reports, and so I hope that you found their comments constructive.

We value the input of all of our reviewers to improve the quality of our publications and RSC Advances is continually seeking to expand its reviewer community.

If you do not currently act as a reviewer for RSC Advances, I invite you to become a reviewer. Please log into your account and add/update your current research interests and send your CV and a reviewer application form to advances@rsc.org. Find out more about becoming a reviewer:

<https://www.rsc.org/journals-books-databases/journal-authors-reviewers/author-responsibilities/#code-of-conduct>

If you do currently review for us, please ensure your account information is up to date. The information you give regarding your research interests and areas of expertise is essential for editors to match submitted manuscripts with reviewers, and to ensure that you are asked to review the most appropriate manuscripts.

You can add/update your research interests by logging into your account (<https://mc.manuscriptcentral.com/rscadv>), clicking on your name at the top of the screen, selecting 'User ID & Password' from the list, and then completing the 'Research Interests' box (at end of page). You may also select a number of keywords describing your particular area(s) of expertise. Under the "Keywords" heading, in the "Search on this list" box you can search the list using the wildcard * for keywords relevant to your area of expertise, e.g. ENZYM* to find keywords related to enzymes.

Please also link your ORCID iD to your account. For a step-by-step guide see:

<https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#attribution-id>

Please contact me if I can be of any assistance.

Yours sincerely,

Dorina Monique Lucillo

Publishing Assistant

Royal Society of Chemistry - RSC Advances

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to